Synthetic biology is seeing rapid advances, but the medical applications have thus far remained largely elusive. But now researchers from the Wyss Institute for Biologically Inspired Engineering at Harvard University and Harvard Medical School (HMS) have developed a tool that can track specific populations of bacteria in the gut of living organisms and document population changes over time.
Australian researchers have developed the first potent new small-molecule inhibitors capable of blocking the activation of apoptotic cell death before it causes damage to mitochondria, they reported in a study published in the Oct. 7, 2019, issue of Nature Chemical Biology.
There's a yin and yang to neoantigens, Alberto Bardelli told the audience at the 2019 annual conference of the European Society of Medical Oncology (ESMO) in Barcelona, Spain, last month. They contribute to tumorigenesis, resistance and tumor heterogeneity. But they are also often specific to tumor cells but not normal cells and "some," he said, "are actionable targets."
LONDON – A paper that raised concerns for the future health of Lulu and Nana, the world's first gene edited babies, has been fully retracted at the request of the authors, after they failed to identify a problem in data from the U.K. Biobank on which their analysis was based.
The emerging methodology of federated learning can overcome many of the ethical and privacy obstacles preventing patient data from being pooled for analysis, according to research published this week. French-American artificial intelligence (AI) specialist Owkin Inc. has demonstrated the technique can be used to apply machine learning to datasets held at different clinical centers. In a paper published in the Oct. 7 online edition of Nature Medicine, they describe how that generated new insights into the histopathology of malignant mesothelioma.
The leucine-repeat rich kinase 2 (Lrrk2) gets most of its attention in the context of Parkinson's disease (PD). Variants in Lrrk2 are a major cause of familial PD (though familial PD makes up only a small fraction of overall PD cases).
Researchers at Princeton University have used a combination of artificial intelligence and synthetic biology to identify and produce biologically active small molecules produced by members of the human microbiome.